Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Metronidazole is a nitroimidazole antibiotic and antiprotozoal drug used to treat anaerobic bacterial and protozoal infections. It is a prodrug that becomes active only inside susceptible, mainly anaerobic, microorganisms and protozoa, where it is reduced to nitroso free radicals that bind DNA, causing strand breaks and inhibiting nucleic acid synthesis. It is widely used for conditions such as trichomoniasis, giardiasis, amebiasis, bacterial vaginosis, intra-abdominal infections, and for surgical prophylaxis. Metronidazole is NOT a molecular target but a therapeutic agent, and should not be confused with molecular targets such as receptors or enzymes.
Reduction within anaerobic microorganisms generates nitroso free radicals. These free radicals induce DNA damage and strand breaks, inhibiting nucleic acid synthesis and leading to cell death.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Metronidazole.